The availability of a wide range of technologically superior bone grafts provides surgeons with the flexibility to choose suitable grafts for specific needs, increasingly making allografts the procedure of choice.
New analysis from Frost & Sullivan (medicaldevices.frost.com), European Markets for Bone Grafts and Bone Cements, finds that the market earned revenues of $641.2 million in 2007 and estimates this to reach $1 498.2 million in 2014.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European markets for bone grafts and bone cements, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
"As manufacturing processes for machined bone become more efficient and are able to extract more value from the same limited supply pool, the number of units sold is expected to increase," says Frost & Sullivan Research Analyst Kezia Jasper. "New product designs attract more surgeons and thereby, boost revenues."
Patients and surgeons also prefer allografts for their other significant advantages such as lower hospital and procedure costs, higher success rates, reduced morbidity, pain and blood loss, and better stability and rehabilitation.
The rise in the number of published clinical studies substantiating the advantages of allografts has also encouraged surgeons to adopt these grafts. They are further impelled by the availability of machined and standard bone grafts, since unlike autografts, they eliminate the need for an additional surgery.
However, the bones and organs in allograft surgeries are mainly sourced from donors who pledge their organs. With the numbers of donors remaining static for almost a decade, there is a crunch in supply of tissues and raw materials for processing.
This public reticence to donate organs is due to a variety of reasons such as religious, social and emotional issues as well as inadequate awareness. Moreover, the availability of specific allografts in certain quantities is partly influenced by the number of donations that are processed.
Non-profit organisations have had bigger success than corporates in procuring tissues, since relatives feel less queasy about donating a body to a non-profit organisation than selling it to commercial organisations. To counter this situation, commercial companies need to establish agreements with non-profit tissue banks to procure tissue.
"Once they collaborate, they could offer high-quality training and education to tissue recovery teams to ensure the donated tissues are collected and refrigerated in time so that there are fewer possibilities of contamination," notes Jasper. "Timely collection of tissues will also improve the testing and screening procedures."
European Markets for Bone Grafts and Bone Cements is part of the Medical Devices Growth Partnership Service program, which also includes research in the following markets: European External Defibrillators Market; European Custom Procedure Trays Market; and Reconstructive Surgeries Market in Europe. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
European Markets for Bone Grafts and Bone Cements M1B8